Back to results
WithdrawnPhase 1

First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)

NCT05921929

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

CHU of Liège - Clinical Pharmacology Unit

Liège, Belgium

View on ClinicalTrials.gov
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM) — TrialFind